Transcatheter Aortic Valve Replacement Outcomes in End-Stage Renal Disease Patients on Hemodialysis Requiring Midodrine.
Publication Title
Struct Heart
Document Type
Article
Publication Date
5-1-2023
Keywords
washington; oregon; montana; california; swedish; pshmc; cards; cards publication; missoula; orange; everett; prmc; End stage renal disease; Midodrine; Survival; Transcatheter aortic valve replacement
Abstract
BACKGROUND: Patients with dialysis-dependent end-stage renal disease (ESRD) taking midodrine may be at high risk for poor outcomes following transcatheter aortic valve replacement (TAVR). We evaluated dialysis-dependent ESRD patients taking midodrine.
METHODS: We conducted a retrospective analysis of non-clinical trial TAVR patients from February 2012 to December 2020 from 11 facilities in a Western US health system. Patient groups included ESRD patients on midodrine before TAVR (ESRD [+M]), ESRD patients without midodrine (ESRD [-M]), and non-ESRD patients. The endpoints of 30-day and 1-year mortality were represented by Kaplan-Meier survival estimator and compared by log-rank test.
RESULTS: Forty-five ESRD (+M), 216 ESRD (-M), and 6898 non-ESRD patients were included. ESRD patients had more comorbid conditions, despite no significant difference in predicted Society of Thoracic Surgeons mortality risk between ESRD (+M) and ESRD (-M) (8.7% vs. 9.2%,
CONCLUSIONS: Our experience suggests ESRD patients on midodrine are a higher acuity population with worse survival after TAVR, compared to ESRD patients not on midodrine. These findings may help with risk stratification for ESRD patients undergoing TAVR.
Clinical Institute
Cardiovascular (Heart)
Clinical Institute
Kidney & Diabetes
Specialty
Center for Cardiovascular Analytics, Research + Data Science (CARDS)
Specialty
Nephrology
Specialty
Cardiology
DOI
10.1016/j.shj.2023.100163